Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

D Chihara, Chan Cheah, JR Westin, LE Fayad, MA Rodriguez, FB Hagemeister, B Pro, P McLaughlin, A Younes, F Samaniego, A Goy, F Cabanillas, H Kantarjian, LW Kwak, ML Wang, JE Ronaguera

Research output: Contribution to journalArticlepeer-review

67 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center'. Together they form a unique fingerprint.

Medicine & Life Sciences